rMark Bio has raised $2.0M in total across 1 funding round.
rMark Bio's investors include Early Light Ventures, Motley Fool Ventures, Howard Tullman, Mark Cuban, MATH Venture Partners.
rMark Bio was a Chicago-based technology company founded in 2015 that developed an AI-powered SaaS platform called Fabric for the life sciences industry, primarily serving pharmaceutical companies, academic institutions, medical device firms, and investment groups.[1][2][3] The platform analyzed global healthcare data alongside internal clinical research to deliver real-time business intelligence, recommending key opinion leaders (KOLs), optimizing partnerships, and providing actionable insights for R&D, commercialization, and stakeholder engagement—reducing data analysis time and costs while aligning strategies across teams.[1][3][6] With around 8 employees and $7 million in annual revenue by 2025, plus $3 million in funding, it gained traction through partnerships like one with West Monroe in recent years before its acquisition by Within3, marking strong growth in AI-driven life sciences tools.[1][2][4]
rMark Bio emerged in 2015 (with some sources noting 2014) when co-founder and CEO Jason Smith identified inefficiencies in how pharma companies identified academic and clinical partners for drug development, relying on manual keyword searches instead of intelligent matching.[1][3][5][7] Smith, leveraging expertise in cognitive computing, built a proprietary deep learning platform using technologies like IBM Watson and Google TensorFlow to personalize KOL recommendations by integrating users' internal data such as CRM, budgets, and trials.[3][6] Early traction came at events like the 2016 Medical Affairs Strategic Summit, where demos showed the platform narrowing thousands of generic KOL search results to just 52 highly relevant ones, proving its value in streamlining partnerships.[3] This beta approach, tailoring features to client needs, fueled initial adoption in a niche but critical pharma workflow.[3]
rMark Bio rode the explosion of AI in life sciences, addressing the need for data-driven stakeholder mapping amid rising pharma R&D costs and complex partnerships in areas like drug development.[2][3] Its timing aligned with the mid-2010s surge in cognitive tools (e.g., Watson, TensorFlow), enabling pharma to shift from broad searches to hyper-personalized insights at a time when medical affairs teams generated vast unstructured data from trials and engagements.[3][4] Market forces like digital transformation pressures and AI's promise for competitive edges in commercialization favored it, as seen in its West Monroe partnership targeting sustainable advantages.[2] By modernizing KOL identification, it influenced the ecosystem, paving the way for integrated platforms like Within3 post-acquisition, which now scales these capabilities globally for deeper stakeholder insights.[4]
rMark Bio's acquisition by Within3 accelerates its tech into a larger enterprise platform, combining Fabric's AI with Within3's virtual engagement tools to deliver 360-degree KOL insights faster for life science firms worldwide.[4] Expect integration to boost efficiency in generating fourfold more insights than traditional methods, capitalizing on AI trends like predictive analytics for R&D and commercialization.[2][4] As life sciences doubles down on data intelligence amid regulatory and market complexities, the combined entity could expand market share, evolving rMark's niche blueprint into a standard for AI-personalized partnerships—transforming how pharma turns healthcare data into real-time strategy.[1][4]
rMark Bio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $2.0M Seed | Early Light Ventures, Motley Fool Ventures, Howard Tullman, Mark Cuban, MATH Venture Partners |
